Compass Pathways Plc ADR (NASDAQ: CMPS) has experienced a rise in its stock price by 4.50% compared to its previous closing price of $3.31. However, the company has seen a gain of 23.53% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-24 that I am moving Compass Pathways plc from Strong Buy to Hold after phase 3 COMP005 data, as results met endpoints but disappointed market expectations. Upcoming catalysts include 26-week COMP006 phase 3 data in 2H 2026 and ongoing PTSD and anorexia programs, but risks remain if future data underwhelms. The treatment resistant depression market in the 7 major markets is expected to reach $6.70 billion by 2035.
Is It Worth Investing in Compass Pathways Plc ADR (NASDAQ: CMPS) Right Now?
The 36-month beta value for CMPS is also noteworthy at 2.12. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CMPS is 84.17M, and at present, short sellers hold a 6.29% of that float. The average trading volume of CMPS on July 08, 2025 was 2.34M shares.
CMPS’s Market Performance
The stock of Compass Pathways Plc ADR (CMPS) has seen a 23.53% increase in the past week, with a -23.65% drop in the past month, and a 27.63% gain in the past quarter. The volatility ratio for the week is 9.72%, and the volatility levels for the past 30 days are at 10.71% for CMPS. The simple moving average for the past 20 days is -6.42% for CMPS’s stock, with a -20.27% simple moving average for the past 200 days.
Analysts’ Opinion of CMPS
Many brokerage firms have already submitted their reports for CMPS stocks, with Evercore ISI repeating the rating for CMPS by listing it as a “In-line.” The predicted price for CMPS in the upcoming period, according to Evercore ISI is $6 based on the research report published on June 23, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see CMPS reach a price target of $11. The rating they have provided for CMPS stocks is “Buy” according to the report published on February 27th, 2025.
RBC Capital Mkts gave a rating of “Outperform” to CMPS, setting the target price at $23 in the report published on July 23rd of the previous year.
CMPS Trading at -12.52% from the 50-Day Moving Average
After a stumble in the market that brought CMPS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.48% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMPS starting from ATAI Life Sciences N.V., who sale 2,660,000 shares at the price of $6.05 back on Sep 26 ’24. After this action, ATAI Life Sciences N.V. now owns 6,905,774 shares of Compass Pathways Plc ADR, valued at $16,093,000 using the latest closing price.
Stock Fundamentals for CMPS
The total capital return value is set at -0.65. Equity return is now at value -60.67, with -43.91 for asset returns.
Based on Compass Pathways Plc ADR (CMPS), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -13.74. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -83.85.
Currently, EBITDA for the company is -178.21 million with net debt to EBITDA at 1.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.18.
Conclusion
In summary, Compass Pathways Plc ADR (CMPS) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
